about
Profiling critical cancer gene mutations in clinical tumor samplesInferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arraysHigh-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell linesRecurrent BRAF mutations in Langerhans cell histiocytosisA landscape of driver mutations in melanomaMutational heterogeneity in cancer and the search for new cancer-associated genesIntegrative analysis of the melanoma transcriptomeMelanoma genome sequencing reveals frequent PREX2 mutationsExome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerThe genomic complexity of primary human prostate cancerThe histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onsetInitial genome sequencing and analysis of multiple myelomaCharacterizing the cancer genome in lung adenocarcinoma.MEK1 mutations confer resistance to MEK and B-RAF inhibition.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkersOncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Response and acquired resistance to everolimus in anaplastic thyroid cancerIntegrative clinical genomics of advanced prostate cancer.Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMapping the hallmarks of lung adenocarcinoma with massively parallel sequencingDiscovery and saturation analysis of cancer genes across 21 tumour typesIntegrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setIntegrated genetic and pharmacologic interrogation of rare cancersThe landscape of somatic copy-number alteration across human cancers.The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityBRAF mutation predicts sensitivity to MEK inhibitionIntegrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanomaThe mutational landscape of head and neck squamous cell carcinomaHighly recurrent TERT promoter mutations in human melanomaCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationAssessing the significance of chromosomal aberrations in cancer: methodology and application to gliomaAssessing the clinical utility of cancer genomic and proteomic data across tumor types.High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingUnraveling the clonal hierarchy of somatic genomic aberrations.
P50
Q21562343-A0C24B1C-8212-4018-9D73-61343F14CFD9Q21563517-961121EC-AB3F-4F9C-B6FD-73FCC0C0AC8AQ23058134-FB74ED88-0E79-47BC-B9EE-5B708B8F9439Q24594344-A464362B-D4F5-41D4-A80D-2B7AC5AE9D4CQ24603357-949A1ABF-963E-4CCD-B378-2BBD5CEB5EB0Q24606956-2B5D1FF2-0177-4096-BC2F-DE1D42530489Q24608060-E128DE1E-7A95-4C83-BF22-C4BC27BCE521Q24610463-D5CFF1C5-596E-4EA4-9320-CAE2684A7EC3Q24616117-67B5A9A1-D58B-40E9-A38D-EAD336FFB42FQ24617949-1FFDF47F-9260-4077-9514-164F26D2D356Q24625220-BBC83A54-2607-4C42-BC1E-7A5017E4695BQ24629117-808635EC-E416-4FFB-896C-E033A7CFB913Q24649926-808B6279-7BAD-4404-A6EB-C5A8D4488ED6Q27777362-B0CCA3D8-80D1-46C2-9DCC-81542CF6C1E9Q27851628-3886FF51-F3AB-4BE2-BFC6-88A07D00D827Q27851896-0DC272AF-D83F-4192-8FCB-B3433837BA92Q27852017-161FF6EE-87ED-42FB-9D02-CC092C4443DCQ27852227-3F0C1AE6-3E5E-4137-B06E-8B3F86C209B4Q27852601-7D6AB146-80A1-420F-9ED1-305D1933ADB5Q27852954-D8328F7E-F664-4BAE-9B6D-490178ACCF0AQ27853005-0190B9F6-BD92-40FA-BE67-FEF5ACD0D0D6Q27853080-DD36CACA-BDD2-4CE6-9781-7F4820FEE0A3Q27853170-EB23D92B-479D-4C43-8CE0-BE938AE7306DQ27853189-7972CECE-9C08-4AB8-982B-49A6D606C208Q28240702-2ACA5281-ED05-4625-A387-96ED780C396BQ28275103-FE7531AC-C103-4F18-8401-EF961E92400FQ28305204-D1E1347F-0999-45AC-B0B7-700037ED1849Q28389579-712E074C-DD71-4C7E-947C-C74D4B0C2D8BQ28829289-42852C83-892C-4EF7-91BE-6AF05C8C8A7DQ29547648-E30B44B8-4EFA-4CA2-A17A-5BD94768BEBDQ29547693-B09B9952-DAD8-4B37-BB99-62EE83C0EF4CQ29614281-5965191F-1A53-4C47-935F-7FBA93335E01Q29614282-11EA4316-CC84-4072-BAD5-40A4E9E8FC0BQ29614654-CF0A205E-7DD7-4102-83CF-33DB4CB5AB17Q29614798-45D27EC2-0E10-477C-8CE8-3E91F6097060Q29615032-8811BAAB-7D95-4987-A3D6-6B742E4309D0Q30014823-00E8154D-8DBD-4358-9F11-74D69059649AQ30487077-435306F8-B860-499D-B7F7-5840ADD4ABAFQ30514084-0F7F210D-BD6E-465B-BBE7-61BE505A86EAQ30587156-86B33EE7-B985-45D9-95DC-8C9201AC0C27
P50
description
researcher
@en
wetenschapper
@nl
name
Levi A Garraway
@en
Levi A Garraway
@nl
type
label
Levi A Garraway
@en
Levi A Garraway
@nl
prefLabel
Levi A Garraway
@en
Levi A Garraway
@nl
P31
P496
0000-0003-3739-0471